Use of Vascular Endothelial Growth Factor Inhibitor, Bevacizumab to Modulate the Outcomes of Trabeculectomy Surgery
Phase 4
30 Years
N/A
30 Years
N/A
Open (Enrolling)
Both
Glaucoma
Both
Glaucoma
Trial Information
Use of Vascular Endothelial Growth Factor Inhibitor, Bevacizumab to Modulate the Outcomes of Trabeculectomy Surgery
Inclusion Criteria:
- any type of glaucoma, except neovascular or inflammatory
- patients requiring trabeculectomy or combined cataract surgery with trabeculectomy
surgery
Exclusion Criteria:
- younger than 30 years of age
- previous ocular surgeries excepting cataract surgeries
- patients who have had or present with intraocular inflammation
- neovascular glaucoma
- patients who are aphakic
- diabetic retinopathy
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Outcome Measure:
post surgery IOP (Intra Ocular Pressure Measurement)
Outcome Time Frame:
one year post surgery
Safety Issue:
No
Principal Investigator
Lesya Shuba, MD PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
CDHA Halifax Nova Scotia Canada
Authority:
Capital District Health Ethics Board Halifax Nova Scotia Canada':'
Study ID:
CD-2007-331
NCT ID:
NCT01229202
Start Date:
July 2008
Completion Date:
June 2012
Related Keywords:
- Glaucoma
- trabeculectomy
- glaucoma surgery
- bevacizumab
- Vascular Endothelial Growth Inhibitor
- glaucoma
- Glaucoma
Name | Location |
|---|
